Financials data is unavailable for this security.
View more
Year on year Neogenomics Inc grew revenues 16.07% from 509.73m to 591.64m while net income improved from a loss of 144.25m to a smaller loss of 87.97m.
Gross margin | 43.54% |
---|---|
Net profit margin | -12.07% |
Operating margin | -14.33% |
Return on assets | -4.68% |
---|---|
Return on equity | -8.38% |
Return on investment | -5.31% |
More ▼
Cash flow in USDView more
In 2023, Neogenomics Inc increased its cash reserves by 30.13%, or 79.31m. Cash Flow from Investing totalled 76.71m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 1.95m for operations while cash generated from financing totalled 4.55m.
Cash flow per share | -0.0396 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 7.09 |
---|---|
Tangible book value per share | 0.2921 |
More ▼
Balance sheet in USDView more
Current ratio | 1.99 |
---|---|
Quick ratio | 1.91 |
Total debt/total equity | 0.595 |
---|---|
Total debt/total capital | 0.373 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 39.64%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 20.06 |